Pune-based Contract Development & Manufacturing Organisation (CDMO), Enzene Biosciences has announced the launch of its first manufacturing site in the United States, located in Hopewell (near Princeton, New Jersey). The site is expected to be ready in June 2024, and customers have already started to reserve capacities for continuous manufacturing and/or fed batch.

Designed to integrate the company’s patented EnzeneX continuous manufacturing technology platform, the plant is situated within the Princeton West Innovation Campus, at the heart of the US Northeast Corridor, within easy reach of several global biotech and pharmaceutical firms. This location is ideal for helping Enzene Biosciences serve emerging innovative, US-based biotech firms looking to benefit from the in-depth expertise in continuous manufacturing.

Spread over 54,000 square feet, this plant will also hold the distinction of being one of the only biologics-focused continuous manufacturing bases to be set up by an Indian firm in the US. The company narrowed down on New Jersey because of its long tradition of supporting pharmaceutical manufacturing excellence. There is also ample availability of highly skilled talent in the region and Enzene Inc. is confident of securing skilled labour for sustained manufacturing operations over the longer term.

Enzene Biosciences aims to gradually expand its operations across the five major markets for biologics and biosimilars, i.e. the EU, US, Canada, Australia, and Japan.